ATRC:NSD-AtriCure Inc. (USD)

EQUITY | Medical Instruments & Supplies | NASDAQ Global Market

Last Closing

USD 36.63

Change

-1.57 (-4.11)%

Market Cap

USD 0.64B

Volume

0.37M

Analyst Target

USD 55.63
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

AtriCure Inc is a medical device company. It develops, manufactures and sells cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac, or heart, tissue.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-12 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ISRG Intuitive Surgical Inc

-0.38 (-0.07%)

USD 180.35B
COO The Cooper Companies, Inc. Com..

-0.12 (-0.12%)

USD 20.95B
HOLX Hologic Inc

-0.58 (-0.73%)

USD 19.12B
ALGN Align Technology Inc

-4.06 (-1.85%)

USD 16.05B
RGEN Repligen Corporation

+1.88 (+1.27%)

USD 7.52B
MMSI Merit Medical Systems Inc

-2.56 (-2.46%)

USD 5.76B
XRAY Dentsply Sirona Inc

-0.42 (-2.36%)

USD 4.76B
ICUI ICU Medical Inc

-3.20 (-1.80%)

USD 4.17B
AZTA Azenta Inc

-1.48 (-3.22%)

USD 2.25B
LMAT LeMaitre Vascular Inc

-0.69 (-0.67%)

USD 2.00B

ETFs Containing ATRC

XHE SPDR® S&P Health Care Eq.. 2.28 % 0.35 %

-1.55 (-1.68%)

USD 0.22B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.63% 62% D 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.63% 62% D 47% F
Trailing 12 Months  
Capital Gain -9.82% 47% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.82% 47% F 31% F
Trailing 5 Years  
Capital Gain 30.40% 67% D+ 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.40% 67% D+ 60% D-
Average Annual (5 Year Horizon)  
Capital Gain 3.39% 42% F 49% F
Dividend Return 3.39% 42% F 45% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 49.11% 58% F 39% F
Risk Adjusted Return 6.90% 44% F 39% F
Market Capitalization 0.64B 74% C 78% C+

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Instruments & Supplies) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 34.48 48% 29%
Price/Book Ratio 4.01 34% 29%
Price / Cash Flow Ratio 421.07 3% 1%
Price/Free Cash Flow Ratio -135.97 97% 98%
Management Effectiveness  
Return on Equity -8.39% 58% 51%
Return on Invested Capital -6.04% 54% 42%
Return on Assets -3.51% 54% 44%
Debt to Equity Ratio 13.00% 65% 68%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector